



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/803,180
		Filing Date	March 18, 2004
		First Named Inventor	CARGILL, Michele, et al.
		Group Art Unit	1645
		Examiner Name	TBA
Sheet 1	of 2	Attorney Docket Number	CL001511

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
STK ↓		DataBase EMBL "Online! 9 June 1995 (1995-06-09), "Homo sapiens (clones HGPCD2 and HGPCD15) pterin-4a-carbinolamine dehydrates (PCBD) gene, complete cds." XP002310444 retrieved from EBI accession no. EM_HUM: L41560; Database accession no. L41560	
		THONY BEAT et al.; "Characterization of the Human PCBD Gene Encoding the Bifunctional Protein Pterin-4-Alpha-Carbinolamine Dehydratase/Dimerization of cofactor for the Transcription Factor HNF-1-Alpha" Biochemical and Biophysical Research Communications, vol. 210, no. 3, 1995, pages 966-973, ISSN: 0006-291X	
		DataBase EMBL "Online!; 9 April 2000 (2000-04-09), "Homo sapiens chromosome 10 clone RP11-29P24 map 10, Working Draft Sequence, 17 unordered pieces." XP002310248 retrieved from EBI accession no. EM_HTG: AC023639	
		DataBase EMBL "Online!; 8 June 2000 (2000-06-08), "Homo sapiens chromosome 10 clone RP11-205C5, complete sequence." XP002310249 retrieved from EBI accession no. EM_HUM: AC069538	
		DataBase EMBL "Online!; 6 September 2001 (2001-09-06), "603189135F1 NIH_MGC_95 Homo sapiens cDNA clone IMAGE: 5260425 5', mRNA sequence." XP002310466 retrieved from EBI accession no. EM_EST: BI548743; Database accession no. BI548743	
		WO 01/11084 A (KIMBERLY ROBERT P; UAB Research Foundation (US); GIBSON ANDREW (US) 15 February 2001 (2001-02-15) page 8, line 5- page 14, line 17 claims 7,8	
		WO 02/074989 A (GOUGH STEPHEN; TODD JOHN (GB); UEDA HIRONORI (GB); CATALYST BIOMEDICA 26 September 2002 (2002-09-26) page 42, line 22- page 45, line 5; claims 1-4	
		MORGAN ANN W et al.; "Fcgamma Receptor Type IIIA is Associated with Rheumatoid Arthritis in Two Distinct Ethnic Groups" Arthritis and Rheumatism, vol.43, no. 10, October 2000 (2000-10), pages 2328-2334, XP002288078; ISSN: 0004-3591	

Examiner Signature	/Stephen Kapushoc/	Date Considered	12/07/2006
--------------------	--------------------	-----------------	------------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

control number.		Complete if Known	
Substitute for form 1449B/PTO		Application Number 10/803,180	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date March 10, 2004	
(use as many sheets as necessary)		First Named Inventor CARGILL, Michele, et al.	
Sheet 2 of 2		Group Art Unit 1645	
Examiner Name TBA		Attorney Docket Number CL001511	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial; symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
STK ↓  V		WALDRON-LYNCH F et al.; "Tumor Necrosis Factor 5' Promoter Single Nucleotide Polymorphisms influence Susceptibility to Rheumatoid Arthritis (RA) in Immunogenetically defined multiplex RA Families; Genes and Immunity; Apr 2001, vol. 2, no. 2, April 2001 (2001-04), pages 82-87, XP009032935; ISSN: 14664879
		YAMADA R et al.; "Association between a single-nucleotide polymorphisms in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients and maximum-likelihood estimation of ..... Effect that two genetic loci have susceptibility to the disease"; American Journal of Human Genetics, American Society of Human Genetics, Chicago, IL, US, vol. 68, no. 3, 2001, pages 674-685, XP002972306; ISSN: 0002-9297
		THONY B, et al.; "Hyperphenylalaninemia with High Levels of 7-Biopterin is associated with Mutations in the PCBD Gene Encoding the Bifunctional Protein Pterin-4A-Carbinolamine Dehydratase and Transcriptional Coactivator (DCOH)."; American Journal of Human Genetics; Jun 1998, vol. 62, No. 6, June 1998 (1998-06), pages 1302-1311, XP002310443; ISSN: 0002-9297
		Copy of International Search Report and Written Opinion dated March 02, 2005

Examiner Signature	/Stephen Kapushoc/	Date Considered	12/07/2006
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.